Review
Medicine, General & Internal
Alexandru Dan Popescu, Mara Carsote, Ana Valea, Andreea Gabriela Nicola, Ionela Teodora Dascalu, Tiberiu Tirca, Jaqueline Abdul-Razzak, Mihaela Jana Tuculina
Summary: Acromegaly-related sub/infertility is associated with suboptimal disease control, hyperprolactinemia, hypogonadotropic hypogonadism, and glucose profile anomalies. This review explores the impact of acromegaly on pregnancy outcomes and discusses management strategies. The level of disease control, family history of diabetes, and body mass index are important predictors of maternal complications. Pharmacotherapy has been shown to be safe and effective in improving pregnancy outcomes.
Article
Radiology, Nuclear Medicine & Medical Imaging
Chayenne H. A. M. Veerman, Hinke Siebinga, Daphne M. V. de Vries-Huizing, Margot E. T. Tesselaar, Jeroen J. M. A. Hendrikx, Marcel P. M. Stokkel, Else A. Aalbersberg
Summary: According to guidelines, long-acting somatostatin analogues (LA-SSAs) should be discontinued prior to peptide receptor radionuclide therapy (PRRT). This study aimed to determine the effect of continued use of LA-SSAs during PRRT on the uptake of [Lu-177]Lu-HA-DOTATATE. The results showed that long-acting octreotide and lanreotide do not interfere with the uptake of [Lu-177]Lu-HA-DOTATATE in tumor lesions, but significantly decrease uptake in healthy liver parenchyma and spleen tissue.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Review
Biochemistry & Molecular Biology
Olesja Rogoza, Kaspars Megnis, Marija Kudrjavceva, Aija Gerina-Berzina, Vita Rovite
Summary: Somatostatin receptors play a crucial role in the treatment of neuroendocrine tumors, delaying tumor progression and regulating hormone overproduction. The expression level of SSTRs has predictive value in therapeutic response and patient survival rate. Future research will focus on other epigenetic regulators affecting somatostatin signaling and combination therapy strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Endocrinology & Metabolism
Maria Fleseriu, Fabienne Langlois, Dawn Shao Ting Lim, Elena V. Varlamov, Shlomo Melmed
Summary: Acromegaly, caused by growth hormone-secreting pituitary adenomas, is usually benign but can be locally invasive and progressive. It leads to a wide range of comorbidities and the normalization of growth hormone and insulin-like growth factor 1 is the primary therapeutic goal. A multimodal approach with surgery, medical therapy, and radiation therapy is required for optimal outcomes.
LANCET DIABETES & ENDOCRINOLOGY
(2022)
Article
Gastroenterology & Hepatology
Boukje T. Bootsma, Victor D. Plat, Tim van de Brug, Daitlin E. Huisman, M. Botti, Peter B. van den Boezem, Bert A. Bonsing, Koop Bosscha, Cornelis H. C. Dejong, Bas Groot-Koerkamp, Jeroen Hagendoorn, Erwin van der Harst, Ignace H. de Hingh, Vincent E. de Meijer, Misha D. Luyer, Vincent B. Nieuwenhuijs, Bobby K. Pranger, Hjalmar C. van Santvoort, Jan H. Wijsman, Barbara M. Zonderhuis, Geert Kazemier, Marc G. Besselink, Freek Daams
Summary: This study investigated the effect of different somatostatin analogues (SA) protocols on the incidence of postoperative pancreatic fistula (POPF) after pancreatoduodenectomy. The study found that the use of lanreotide in all patients undergoing pancreatoduodenectomy may have a protective effect on POPF development, and protocols for high-risk patients might be favorable as well. However, further studies are needed to confirm these findings.
Review
Biochemistry & Molecular Biology
Sofie Eline Tollefsen, Ole Solheim, Patricia Mjones, Sverre Helge Torp
Summary: Meningioma is a common brain tumor without approved specific drugs. This study aims to compile the current insights of somatostatin analogs for treating patients with meningioma. A systematic search was conducted, and 17 eligible studies were evaluated. Although the efficacy of somatostatin analogs remains unclear, some studies suggest that they may be a last-option treatment for severely ill-patients. However, a controlled study or randomized clinical trial is needed to establish their efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Endocrinology & Metabolism
Karina Zanlorenzi Basso Manosso, Carolina Labigalini Sampaio, Leandro Kasuki, Ximene Antunes, Monica R. Gadelha, Cesar Luiz Boguszewski
Summary: This study aimed to compare biochemical and tumor response rates between two reference centers for pituitary diseases in Brazil after primary and adjuvant therapy with somatostatin receptor ligands (SRL) in acromegaly. The results showed that there was no difference in the proportion of good responders in tumor shrinkage between the two centers when considering only IGF-I levels, but significant difference was found in the classification of full responders when both IGF-I and rGH levels were taken into account, with Center I showing a higher discrepancy.
Article
Medicine, Research & Experimental
Brooke Harrow, Francis Fagnani, Camille Nevoret, Xuan-Mai Truong-Thanh, Marie de Zelicourt, Louis de Mestier
Summary: This retrospective cohort study compared the use of lanreotide autogel (LAN) and octreotide long-acting release (OCT) in patients with neuroendocrine tumors (NETs) using a French claims database. The results showed that patients receiving LAN had longer treatment duration, lower treatment discontinuation rate, and fewer incidences of dose above recommended level and rescue medication use.
ADVANCES IN THERAPY
(2022)
Review
Endocrinology & Metabolism
Monica R. Gadelha, Ana Carolina Gadelha, Leandro Kasuki
Summary: The treatment of acromegaly has advanced significantly in recent decades, but there are still patients who do not respond to current treatments, highlighting the need for improved treatment burden. Fortunately, there are new treatments in development that may enhance treatment efficacy and convenience.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Marek Bolanowski, Alicja Hubalewska-Dydejczyk, Beata Kos-Kudla, Marek Ruchala, Przemyslaw Witek, Wojciech Zgliczynski, Aude Houchard, Marta Bartmanska
Summary: This study evaluated the quality of life in patients with acromegaly treated with lanreotide autogel over a period of two years. The results showed that symptoms remained stable, hormonal control status did not change significantly, and overall treatment satisfaction was high. While the total AcroQoL score remained stable, there were improvements in the psychological appearance subscore.
ENDOKRYNOLOGIA POLSKA
(2021)
Review
Endocrinology & Metabolism
Giovanni Tulipano, Andrea Giustina
Summary: Autophagy is an important cellular process involved in degradation and recycling, regulated by various stimuli and having complex roles in tumor cells. Research on autophagy in the pituitary gland and pituitary tumors is still relatively limited, but gaining attention for its potential implications.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
(2021)
Article
Endocrinology & Metabolism
Mirela-Diana Ilie, Antoine Tabarin, Alexandre Vasiljevic, Jean-Francois Bonneville, Lucile Moreau-Grange, Franck Schillo, Brigitte Delemer, Anne Barlier, Dominique Figarella-Branger, Segolene Bisot-Locard, Alexandre Santos, Philippe Chanson, Gerald Raverot
Summary: This study aimed to explore the factors related to SRLs in the treatment of acromegaly and confirmed that SST2A and adenoma granularity are good predictors of response to octreotide. In addition, the optimization of MRI sequences is important for using T2WSI as a predictor of treatment response.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Daniela Esposito, Daniel S. Olsson, Stefan Franzen, Mervete Miftaraj, Jonatan Natman, Soffia Gudbjornsdottir, Gudmundur Johannsson
Summary: This study suggests that the presence of diabetes in patients with acromegaly is associated with increased overall mortality, cardiovascular mortality, and morbidity.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Leonidas Nikolaos Diamantopoulos, Faidon-Marios Laskaratos, Markos Kalligeros, Ruchir Shah, Shaunak Navalkissoor, Gopinath Gnanasegaran, Jamie Banks, Jack Smith, Benjamin Jacobs, Michail Galanopoulos, Dalvinder Mandair, Martyn Caplin, Christos Toumpanakis
Summary: In this study, above-label doses of somatostatin analogs showed promising antiproliferative effects in patients with inoperable/metastatic gastroenteropancreatic neuroendocrine tumors. Symptomatic improvement and disease control were observed in some patients after 3-weekly administration, with certain factors associated with inferior or better progression-free survival. Higher doses of SSAs may be beneficial as a bridge to other treatments, particularly for patients with specific tumor characteristics.
NEUROENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Angela Lamarca, Jorge Barriuso, Angel Castano, Marta Benavent, Vicente Alonso, Maria del Carmen Riesco, Teresa Alonso-Gordoa, Ana Custodio, Manuel Sanchez Canovas, Jorge Hernando, Carlos Lopez, Adelaida La Casta, Ana Fernandez Montes, Monica Marazuela, Guillermo Crespo, Jose Angel Diaz, Eduardo Feliciangeli, Javier Gallego, Marta Llanos, Angel Segura, Felip Vilardell, Juan Carlos Percovich, Enrique Grande, Jaume Capdevila, Juan Valle, Rocio Garcia-Carbonero
Summary: This study evaluated the external validity of RCTs examining SSAs in the real world, as well as the main effect-modifying factors. The results indicate that both octreotide LAR and lanreotide autogel had a similar effect on PFS, making them valid alternatives in patients with well-differentiated, metastatic GEP-NENs.
NEUROENDOCRINOLOGY
(2022)